Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia.
BACKGROUND
Atrial fibrillation (AF) is the most common chronic rhythm disorder. Patients with AF are at an increased risk of ischemic stroke. Therefore, optimal anticoagulation is essential to reduce the risk of stroke. The aim of this study was to assess the level of anticoagulation control achieved in patients with nonvalvular AF receiving medical care in a tertiary care hospital.


METHODS
This was a retrospective cohort study in ambulatory care clinics at tertiary care hospital in Saudi Arabia. We included 110 nonvalvular AF patients treated with warfarin for at least 3 months at King Abdulaziz Medical City, Riyadh, Saudi Arabia, between May 1, 2012, and July 31, 2012. Thereafter, international normalized ratio results were collected for 1 year. Anticoagulation control was assessed by calculating time within therapeutic range (TTR) as per the Rosendaal method.


RESULTS
The mean age was 64.9 ± 16.5 years; 60.9% were female. The mean TTR was 59%. Almost one third of the patients (32.7%) had poor anticoagulation control; TTR of <50%. Poor anticoagulation control was significantly associated with higher CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score (p = 0.043). TTR was not significantly different between men and women. Similarly, TTR was not associated with age or duration of anticoagulation. There was no adequate information to assess the effect of other factors such as diet, compliance, and level of education on anticoagulation. Thirty-one patients (28.2%) had a history of prior stroke. The overall quality of anticoagulation was not significantly different between patients with and without stroke, (TTR was 56.3% and 60.1%, respectively; p = 0.46).


CONCLUSIONS
Quality of anticoagulation in patients with AF receiving medical care in a tertiary care hospital was suboptimal, with nearly 40% of the time spent outside the therapeutic range. Methods to improve anticoagulation control among patients with AF should be implemented.
Pharmaceutical Care Department, King Abdulaziz Cardiac Center, King Abdulaziz Medical City, Ministry of National Guard, Saudi Arabia.
Sarah M
SM
Alyousif
King Abdulaziz Cardiac Center, King Abdulaziz Medical City, Ministry of National Guard, Saudi Arabia.
Ahmed A
AA
Alsaileek
Anticoagulation; Atrial fibrillation; Rosendaal; Time in therapeutic range; Warfarin
Thromb Haemost. 1993 Mar 1;69(3):236-9
8470047
Chest. 2008 Jun;133(6 Suppl):546S-592S
18574273
Arch Intern Med. 1998 Aug 10-24;158(15):1641-7
9701098
J Health Commun. 2014;19 Suppl 2:19-28
25315581
Ann Intern Med. 2007 Jun 19;146(12):857-67
17577005
J Manag Care Pharm. 2009 Apr;15(3):244-52
19326955
Thromb Res. 2009 May;124(1):37-41
19062079
J Manag Care Pharm. 2006 Oct;12(8):640-8
17269842
J Thromb Thrombolysis. 2008 Aug;26(1):14-21
17616845
Arch Intern Med. 1987 Sep;147(9):1561-4
3632164
Chest. 2004 Dec;126(6):1938-45
15596696
J Thromb Haemost. 2008 Oct;6(10):1647-54
18853483
N Engl J Med. 2009 Sep 17;361(12):1139-51
19717844
Europace. 2015 Aug;17(8):1223-8
25995397
Chest. 2006 May;129(5):1155-66
16685005
J Clin Pharmacol. 2005 Feb;45(2):127-32
15647404
Int J Clin Exp Med. 2015 Jun 15;8(6):8384-97
26309492
CMAJ. 2003 Aug 19;169(4):293-8
12925422
Clin Ther. 2012 Jul;34(7):1511-20
22717417
Circ J. 2014;78(6):1342-8
24717234
J Cardiovasc Pharmacol. 2011 Jul;58(1):87-90
21558883
Lancet. 1994 Mar 19;343(8899):687-91
7907677